AXIM BIOTECHNOLOGIES, INC. (AXIM) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US05463V1008

Price
0.00 USD
Market cap
1.02 m USD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
9.18 %
Return on assets (ROA)
-36.25 %

AXIM BIOTECHNOLOGIES, INC. financials

Fiscal year20242025
Revenue70,458.00 USD–
Gross profit-369,273.00 USD-427,369.00 USD
Operating income-1.76 m USD-1.32 m USD
Net income-3.51 m USD-1.04 m USD
Diluted EPS – continuing operations–-0.00 USD

Full history since 2010, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About AXIM BIOTECHNOLOGIES, INC.

AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin ADDE test. It also operates a full-service center for custom biomarker and biopharmaceutical research, custom assay development, clinical sample testing, and precision data delivery. In addition, the company develops a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring, as well as COVID-19 rapid diagnostic tools. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.